Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › U.S. missile stockpiles dwindle. And, FDA weighs...
Business & Finance

U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech

U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech
NPR News Wednesday 05 August 2026, 11:54 UTC By Brittney Melton 1 min read
Key Points

The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.(Image credit: Sam Yeh)

The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.

(Image credit: Sam Yeh)

U.S. (LOCATION) FDA (ORG) The U.S. Army's (ORG) the Food and Drug Administration (ORG) Sam Yeh (PERSON)
Originally published by NPR News Read original →

Related Stories

Fox won't renegotiate NFL media rights before current deal expires, CEO Lachlan Murdoch says

Fox won't negotiate a new NFL media rights deal before 2030, when its current contract with the league expires via an opt-out clause, Chief Executive Officer Lachlan Murdoch said during a Thursday earnings conference call. The NFL has held preliminary discussions with both Fox and CBS-parent Paramount Skydance about reworking the deals to eliminate the league's opt-out clause and raise the cost of the live rights, CNBC previously reported. Fox and CBS own the NFL's Sunday afternoon packages...

CNBC 5m ago

Datadog’s stock slides after earnings. This is what’s nagging at investors.

The cloud-monitoring company faced a high bar due to its strong stock performance this year and ended up beating expectations by less than it did in the prior quarter.

MarketWatch 16m ago

SpaceX shares slip as lockup expiry adds to post-IPO woes

SpaceX shares slip as lockup expiry adds to post-IPO woes Aug 6 : SpaceX shares fell on Thursday, as investors braced for a potential bout of insider stock sales that could heap fresh pressure on a company already enduring a bumpy ride since listing. The shares were last trading down 1.3 per cent at $106.45. When a company goes public, certain shareholders - typically executives, employees and early investors - are often restricted from selling their shares for up to 180 days, to limit...

Channel News Asia 16m ago

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

The diverging paths of two GLP-1 drugmakers were on full display this week. Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, sending shares higher on Wednesday, they punished Novo a day earlier – underscoring a growing divide in Wall Street's confidence in the two obesity drug leaders.

CNBC 17m ago